CovidSeniorV1, Main, Exploration, bibRecord, 000624

Effective Use of Angiotensin II in Coronavirus Disease 19-Associated Mixed Shock State: A Case Report.

Identifieur interne : 000624 ( Main/Exploration ); précédent : 000623; suivant : 000625

Effective Use of Angiotensin II in Coronavirus Disease 19-Associated Mixed Shock State: A Case Report.

Auteurs : Kevin A. Bobeck [États-Unis] ; Arthur W. Holtzclaw ; Tara E. Brown ; Paul A. Clark

Source :

A&A practice [ 2575-3126 ] ; 2020.

RBID : pubmed:32784326

Descripteurs français

KwdFr :
- Angiotensine-II (usage thérapeutique), Betacoronavirus (MeSH), Choc (traitement médicamenteux), Choc (étiologie), Femelle (MeSH), Humains (MeSH), Infections à coronavirus (complications), Pandémies (MeSH), Pneumopathie virale (complications), Sujet âgé de 80 ans ou plus (MeSH), Vasoconstricteurs (usage thérapeutique).
MESH :
- traitement médicamenteux : Choc.
- usage thérapeutique : Angiotensine-II, Infections à coronavirus, Pneumopathie virale, Vasoconstricteurs.
- étiologie : Choc.
- Betacoronavirus, Femelle, Humains, Pandémies, Sujet âgé de 80 ans ou plus.

English descriptors

KwdEn :
- Aged, 80 and over (MeSH), Angiotensin II (therapeutic use), Betacoronavirus (MeSH), Coronavirus Infections (complications), Female (MeSH), Humans (MeSH), Pandemics (MeSH), Pneumonia, Viral (complications), Shock (drug therapy), Shock (etiology), Vasoconstrictor Agents (therapeutic use).
MESH :
- chemical , therapeutic use : Angiotensin II, Vasoconstrictor Agents.
- complications : Coronavirus Infections, Pneumonia, Viral.
- drug therapy : Shock.
- etiology : Shock.
- Aged, 80 and over, Betacoronavirus, Female, Humans, Pandemics.

Abstract

The rapid spread of Coronavirus Disease 2019 (COVID-19) has sparked a search for effective therapies. The discovery that the virus binds the angiotensin-converting enzyme 2 (ACE2) receptor has led to investigation of the renin-angiotensin system for possible therapeutic targets. We present a case of an elderly woman with multiple comorbidities who developed severe acute respiratory distress syndrome (ARDS), a cardiomyopathy, and vasodilatory shock secondary to COVID-19 and was treated with exogenous angiotensin II. She rapidly demonstrated significant hemodynamic improvement without noted adverse effects. Thus, we propose further investigation into possible benefits of angiotensin II in shock secondary to COVID-19.

DOI: 10.1213/XAA.0000000000001221
PubMed: 32784326
PubMed Central: PMC7172437

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000706
to stream Main, to step Curation: 000706

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effective Use of Angiotensin II in Coronavirus Disease 19-Associated Mixed Shock State: A Case Report.</title>
<author><name sortKey="Bobeck, Kevin A" sort="Bobeck, Kevin A" uniqKey="Bobeck K" first="Kevin A" last="Bobeck">Kevin A. Bobeck</name>
<affiliation wicri:level="2"><nlm:affiliation>From the Departments of *Internal Medicine †Pulmonary, Walter Reed National Military Medical Center, Bethesda, Maryland.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>From the Departments of *Internal Medicine †Pulmonary, Walter Reed National Military Medical Center, Bethesda</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Holtzclaw, Arthur W" sort="Holtzclaw, Arthur W" uniqKey="Holtzclaw A" first="Arthur W" last="Holtzclaw">Arthur W. Holtzclaw</name>
</author>
<author><name sortKey="Brown, Tara E" sort="Brown, Tara E" uniqKey="Brown T" first="Tara E" last="Brown">Tara E. Brown</name>
</author>
<author><name sortKey="Clark, Paul A" sort="Clark, Paul A" uniqKey="Clark P" first="Paul A" last="Clark">Paul A. Clark</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32784326</idno>
<idno type="pmid">32784326</idno>
<idno type="doi">10.1213/XAA.0000000000001221</idno>
<idno type="pmc">PMC7172437</idno>
<idno type="wicri:Area/Main/Corpus">000706</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000706</idno>
<idno type="wicri:Area/Main/Curation">000706</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000706</idno>
<idno type="wicri:Area/Main/Exploration">000706</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Effective Use of Angiotensin II in Coronavirus Disease 19-Associated Mixed Shock State: A Case Report.</title>
<author><name sortKey="Bobeck, Kevin A" sort="Bobeck, Kevin A" uniqKey="Bobeck K" first="Kevin A" last="Bobeck">Kevin A. Bobeck</name>
<affiliation wicri:level="2"><nlm:affiliation>From the Departments of *Internal Medicine †Pulmonary, Walter Reed National Military Medical Center, Bethesda, Maryland.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>From the Departments of *Internal Medicine †Pulmonary, Walter Reed National Military Medical Center, Bethesda</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Holtzclaw, Arthur W" sort="Holtzclaw, Arthur W" uniqKey="Holtzclaw A" first="Arthur W" last="Holtzclaw">Arthur W. Holtzclaw</name>
</author>
<author><name sortKey="Brown, Tara E" sort="Brown, Tara E" uniqKey="Brown T" first="Tara E" last="Brown">Tara E. Brown</name>
</author>
<author><name sortKey="Clark, Paul A" sort="Clark, Paul A" uniqKey="Clark P" first="Paul A" last="Clark">Paul A. Clark</name>
</author>
</analytic>
<series><title level="j">A&A practice</title>
<idno type="eISSN">2575-3126</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged, 80 and over (MeSH)</term>
<term>Angiotensin II (therapeutic use)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Coronavirus Infections (complications)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (complications)</term>
<term>Shock (drug therapy)</term>
<term>Shock (etiology)</term>
<term>Vasoconstrictor Agents (therapeutic use)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Angiotensine-II (usage thérapeutique)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Choc (traitement médicamenteux)</term>
<term>Choc (étiologie)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Infections à coronavirus (complications)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (complications)</term>
<term>Sujet âgé de 80 ans ou plus (MeSH)</term>
<term>Vasoconstricteurs (usage thérapeutique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiotensin II</term>
<term>Vasoconstrictor Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Shock</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Shock</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Choc</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Angiotensine-II</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
<term>Vasoconstricteurs</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Choc</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged, 80 and over</term>
<term>Betacoronavirus</term>
<term>Female</term>
<term>Humans</term>
<term>Pandemics</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Betacoronavirus</term>
<term>Femelle</term>
<term>Humains</term>
<term>Pandémies</term>
<term>Sujet âgé de 80 ans ou plus</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The rapid spread of Coronavirus Disease 2019 (COVID-19) has sparked a search for effective therapies. The discovery that the virus binds the angiotensin-converting enzyme 2 (ACE2) receptor has led to investigation of the renin-angiotensin system for possible therapeutic targets. We present a case of an elderly woman with multiple comorbidities who developed severe acute respiratory distress syndrome (ARDS), a cardiomyopathy, and vasodilatory shock secondary to COVID-19 and was treated with exogenous angiotensin II. She rapidly demonstrated significant hemodynamic improvement without noted adverse effects. Thus, we propose further investigation into possible benefits of angiotensin II in shock secondary to COVID-19.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32784326</PMID>
<DateCompleted><Year>2020</Year>
<Month>08</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>08</Month>
<Day>24</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2575-3126</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>14</Volume>
<Issue>6</Issue>
<PubDate><Year>2020</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>A&A practice</Title>
<ISOAbbreviation>A A Pract</ISOAbbreviation>
</Journal>
<ArticleTitle>Effective Use of Angiotensin II in Coronavirus Disease 19-Associated Mixed Shock State: A Case Report.</ArticleTitle>
<Pagination><MedlinePgn>e01221</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1213/XAA.0000000000001221</ELocationID>
<Abstract><AbstractText>The rapid spread of Coronavirus Disease 2019 (COVID-19) has sparked a search for effective therapies. The discovery that the virus binds the angiotensin-converting enzyme 2 (ACE2) receptor has led to investigation of the renin-angiotensin system for possible therapeutic targets. We present a case of an elderly woman with multiple comorbidities who developed severe acute respiratory distress syndrome (ARDS), a cardiomyopathy, and vasodilatory shock secondary to COVID-19 and was treated with exogenous angiotensin II. She rapidly demonstrated significant hemodynamic improvement without noted adverse effects. Thus, we propose further investigation into possible benefits of angiotensin II in shock secondary to COVID-19.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bobeck</LastName>
<ForeName>Kevin A</ForeName>
<Initials>KA</Initials>
<AffiliationInfo><Affiliation>From the Departments of *Internal Medicine †Pulmonary, Walter Reed National Military Medical Center, Bethesda, Maryland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Holtzclaw</LastName>
<ForeName>Arthur W</ForeName>
<Initials>AW</Initials>
</Author>
<Author ValidYN="Y"><LastName>Brown</LastName>
<ForeName>Tara E</ForeName>
<Initials>TE</Initials>
</Author>
<Author ValidYN="Y"><LastName>Clark</LastName>
<ForeName>Paul A</ForeName>
<Initials>PA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>A A Pract</MedlineTA>
<NlmUniqueID>101714112</NlmUniqueID>
<ISSNLinking>2575-3126</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014662">Vasoconstrictor Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>11128-99-7</RegistryNumber>
<NameOfSubstance UI="D000804">Angiotensin II</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000804" MajorTopicYN="N">Angiotensin II</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012769" MajorTopicYN="N">Shock</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014662" MajorTopicYN="N">Vasoconstrictor Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>8</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>8</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>8</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32784326</ArticleId>
<ArticleId IdType="doi">10.1213/XAA.0000000000001221</ArticleId>
<ArticleId IdType="pii">02054229-202004000-00039</ArticleId>
<ArticleId IdType="pmc">PMC7172437</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Crit Care. 2017 Feb;37:206-210</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27969572</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Mar 23;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32203977</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care Med. 2018 Jun;46(6):949-957</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29509568</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Microbiol. 2020 Apr;5(4):562-569</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32094589</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Pept. 2012;2012:256294</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22536270</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care. 2018 Oct 28;22(1):274</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30368243</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci China Life Sci. 2020 Mar;63(3):364-374</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32048163</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Oral Sci. 2020 Feb 24;12(1):8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32094336</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1723-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21108554</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2017 Dec 28;377(26):2604</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29281568</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Heart Fail. 2016 Jan;18(1):8-27</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26548803</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anesth Analg. 2020 Jul;131(1):102-105</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32209811</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2012;7(4):e35797</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22563403</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
</region>
</list>
<tree><noCountry><name sortKey="Brown, Tara E" sort="Brown, Tara E" uniqKey="Brown T" first="Tara E" last="Brown">Tara E. Brown</name>
<name sortKey="Clark, Paul A" sort="Clark, Paul A" uniqKey="Clark P" first="Paul A" last="Clark">Paul A. Clark</name>
<name sortKey="Holtzclaw, Arthur W" sort="Holtzclaw, Arthur W" uniqKey="Holtzclaw A" first="Arthur W" last="Holtzclaw">Arthur W. Holtzclaw</name>
</noCountry>
<country name="États-Unis"><region name="Maryland"><name sortKey="Bobeck, Kevin A" sort="Bobeck, Kevin A" uniqKey="Bobeck K" first="Kevin A" last="Bobeck">Kevin A. Bobeck</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000624 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000624 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidSeniorV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32784326
   |texte=   Effective Use of Angiotensin II in Coronavirus Disease 19-Associated Mixed Shock State: A Case Report.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32784326" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidSeniorV1

This area was generated with Dilib version V0.6.37.
Data generation: Thu Oct 15 09:49:45 2020. Site generation: Wed Jan 27 17:10:23 2021

	Serveur d'exploration sur la COVID chez les séniors
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la COVID chez les séniors

Effective Use of Angiotensin II in Coronavirus Disease 19-Associated Mixed Shock State: A Case Report.

Effective Use of Angiotensin II in Coronavirus Disease 19-Associated Mixed Shock State: A Case Report.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki